Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/30104% above fair value
$168.08+0.13 (+0.08%)
Close on Nov 13, 2026Market cap $208.48BP/E –Yield 1.88%
Gilead Sciences total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Gilead Sciences's total debt was $26.23B at Sep 30, 2026. For fiscal 2025 it was $24.94B, down 6.6% from the year before. Over ten years it grew 1.2% a year on average. The highest annual figure on record is $33.54B in fiscal 2017.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.94B | -6.6% |
| FY2024 | Dec 31, 2024 | $26.71B | +6.9% |
| FY2023 | Dec 31, 2023 | $24.99B | -1.0% |
| FY2022 | Dec 31, 2022 | $25.23B | -5.5% |
| FY2021 | Dec 31, 2021 | $26.70B | -15.0% |
| FY2020 | Dec 31, 2020 | $31.40B | +27.7% |
| FY2019 | Dec 31, 2019 | $24.59B | -10.0% |
| FY2018 | Dec 31, 2018 | $27.32B | -18.5% |
| FY2017 | Dec 31, 2017 | $33.54B | +27.3% |
| FY2016 | Dec 31, 2016 | $26.35B | +19.5% |
| FY2015 | Dec 31, 2015 | $22.06B | +77.8% |
| FY2014 | Dec 31, 2014 | $12.40B | +86.9% |
| FY2013 | Dec 31, 2013 | $6.64B | -19.3% |
| FY2012 | Dec 31, 2012 | $8.22B | +8.1% |
| FY2011 | Dec 31, 2011 | $7.61B | +1077.0% |
| FY2010 | Dec 31, 2010 | $646.35M | +11468.7% |
| FY2009 | Dec 31, 2009 | $5.59M | -0.8% |
| FY2008 | Dec 31, 2008 | $5.63M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $26.23B | +5.2% |
| Q2 FY2026 | Jun 30, 2026 | $26.25B | +5.2% |
| Q1 FY2026 | Mar 31, 2026 | $22.17B | -11.1% |
| Q4 FY2025 | Dec 31, 2025 | $24.94B | -6.6% |
| Q3 FY2025 | Sep 30, 2025 | $24.94B | +7.3% |
| Q2 FY2025 | Jun 30, 2025 | $24.95B | +6.8% |
| Q1 FY2025 | Mar 31, 2025 | $24.95B | -1.0% |
| Q4 FY2024 | Dec 31, 2024 | $26.71B | +6.9% |
| Q3 FY2024 | Sep 30, 2024 | $23.25B | -6.9% |
| Q2 FY2024 | Jun 30, 2024 | $23.35B | -7.5% |
| Q1 FY2024 | Mar 31, 2024 | $25.19B | -0.2% |
| Q4 FY2023 | Dec 31, 2023 | $24.99B | -1.0% |
| Q3 FY2023 | Sep 30, 2023 | $24.98B | -1.0% |
| Q2 FY2023 | Jun 30, 2023 | $25.25B | -3.7% |
| Q1 FY2023 | Mar 31, 2023 | $25.24B | -3.7% |
| Q4 FY2022 | Dec 31, 2022 | $25.23B | -5.5% |
| Q3 FY2022 | Sep 30, 2022 | $25.22B | -8.9% |
| Q2 FY2022 | Jun 30, 2022 | $26.22B | -13.1% |
| Q1 FY2022 | Mar 31, 2022 | $26.21B | -13.1% |
| Q4 FY2021 | Dec 31, 2021 | $26.70B | -15.0% |
| Q3 FY2021 | Sep 30, 2021 | $27.69B | -5.5% |
| Q2 FY2021 | Jun 30, 2021 | $30.18B | +25.2% |
| Q1 FY2021 | Mar 31, 2021 | $30.17B | +25.2% |
| Q4 FY2020 | Dec 31, 2020 | $31.40B | +27.7% |
| Q3 FY2020 | Sep 30, 2020 | $29.29B | +19.1% |
| Q2 FY2020 | Jun 30, 2020 | $24.10B | -7.6% |
| Q1 FY2020 | Mar 31, 2020 | $24.10B | -9.3% |
| Q4 FY2019 | Dec 31, 2019 | $24.59B | -10.0% |
| Q3 FY2019 | Sep 30, 2019 | $24.59B | -10.0% |
| Q2 FY2019 | Jun 30, 2019 | $26.08B | -10.2% |
| Q1 FY2019 | Mar 31, 2019 | $26.58B | -8.5% |
| Q4 FY2018 | Dec 31, 2018 | $27.32B | -18.5% |
| Q3 FY2018 | Sep 30, 2018 | $27.32B | -6.6% |
| Q2 FY2018 | Jun 30, 2018 | $29.06B | +10.5% |
| Q1 FY2018 | Mar 31, 2018 | $29.05B | +10.4% |
| Q4 FY2017 | Dec 31, 2017 | $33.54B | +27.3% |
| Q3 FY2017 | Sep 30, 2017 | $29.26B | – |
| Q2 FY2017 | Jun 30, 2017 | $26.30B | – |
| Q1 FY2017 | Mar 31, 2017 | $26.32B | – |
| Q4 FY2016 | Dec 31, 2016 | $26.35B | – |
See a number that looks wrong?